CHAPTER 19 – Antisense Downregulation of the Apoptosis–Related Bcl-2 and Bcl-xl Proteins: A New Approach to Cancer Therapy
作者： IRINA V. LEBEDEVA , C.A. STEIN
DOI: 10.1016/B978-012437551-2/50020-3
关键词:
摘要: Members of the bcl-2 family genes are thought to be central regulators apoptosis. Overexpression antiapoptotic proteins, such as Bcl-2 and Bcl-xL, contributes not only development cancer but also its resistance against a wide variety anticancer agents. Thus, downregulation Bcl-xL can potentially used improve therapeutic approaches advanced cancer. The use antisense biotechnology downregulate bcl members in diverse cancers vitro vivo is reviewed. effects potential limitations strategies discussed context critical view recent research field.
springer.com
sci-hub.st 参考文章(199)
F. E. Cotter, P. Johnson, G. Morgan, P. Hall, J. K. Cowell, C. Pocock, N. Al Mahdi, Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model Oncogene. ,vol. 9, pp. 3049- 3055 ,(1994)
Angelo Nicolin, Gianfranco Canti, Alessandro Quattrone, Susanna Morelli, Angela Alama, Elena Copreni, Lei Gong, Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line. Anti-cancer Drug Design. ,vol. 11, pp. 1- 14 ,(1996)
SJ Korsmeyer, Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. ,vol. 80, pp. 879- 886 ,(1992) , 10.1182/BLOOD.V80.4.879.BLOODJOURNAL804879
Philip L. Simonian, Didier A.M. Grillot, Gabriel Nuñez, Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death Blood. ,vol. 90, pp. 1208- 1216 ,(1997) , 10.1182/BLOOD.V90.3.1208
L. A. O'Reilly, D. C. Huang, A. Strasser, The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. The EMBO Journal. ,vol. 15, pp. 6979- 6990 ,(1996) , 10.1002/J.1460-2075.1996.TB01090.X
Thomas A, El Rouby S, Krajewski S, Reed Jc, Newcomb Ew, Potmesil M, Silber R, Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. ,vol. 12, pp. 1055- 1062 ,(1996)
Goluboff Et, Buttyan R, Dorai T, Olsson Ca, Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Research. ,vol. 17, pp. 3307- 3312 ,(1997)
L. H. Boise, A. R. Gottschalk, J. Quintáns, C. B. Thompson, Bcl-2 and Bcl-2-Related Proteins in Apoptosis Regulation Current Topics in Microbiology and Immunology. ,vol. 200, pp. 107- 121 ,(1995) , 10.1007/978-3-642-79437-7_8
AJ Minn, CM Rudin, LH Boise, CB Thompson, Expression of Bcl-xL Can Confer a Multidrug Resistance Phenotype Blood. ,vol. 86, pp. 1903- 1910 ,(1995) , 10.1182/BLOOD.V86.5.1903.BLOODJOURNAL8651903
Krajewski S, Krajewska M, Fenoglio-Preiser Cm, Stemmerman G, Reed Jc, Song K, Macdonald Js, Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach American Journal of Pathology. ,vol. 149, pp. 1449- 1457 ,(1996)